U
TARO

UBS’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

UBS’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$31K Buy
+200
New +$30.1K ﹤0.01% 7441

Other funds holding TARO

ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
GCM
Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AIM
Assured Investment Management New York $79.5M AUM 115.55% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS's TARO Position: Q3 2014 in Review

UBS reduced its Taro Pharmaceutical Industries Ltd. (TARO) stake by 29% in Q3 2014, selling an estimated $911K and leaving 15,150 shares worth $2.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2766.

UBS first reported a position in TARO in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.97M in Q2 2014. 82 funds tracked by Wall St. Rank hold TARO as of Q3 2014.

  • UBS held 15,150 shares of Taro Pharmaceutical Industries Ltd. worth $2.33M as of Q3 2014.
  • UBS sold 6,053 Taro Pharmaceutical Industries Ltd. shares in Q3 2014, an estimated $911K.
  • Taro Pharmaceutical Industries Ltd. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2766 holding.
  • UBS first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2013 and has held it in 6 quarters since.
  • UBS's Taro Pharmaceutical Industries Ltd. position peaked at $2.97M in Q2 2014.
  • 82 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.